-+ 0.00%
-+ 0.00%
-+ 0.00%

PASITHEA THERAPEUTICS ANNOUNCES GRANT OF FAST TRACK DESIGNATION BY FDA TO PAS-004 FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) CAUSING SIGNIFICANT MORBIDITY

Reuters·04/01/2026 11:01:00

Please log in to view news